Structure Therapeutics (GPCR) Non-Current Assets (2022 - 2026)
Structure Therapeutics (GPCR) posted quarterly Non-Current Assets of $17.5 million for Q1 2026, up 3.54% year-over-year from $16.9 million in Q1 2025, and up 28.73% quarter-over-quarter from $13.6 million in Q4 2025.
Structure Therapeutics (GPCR) Non-Current Assets (2022 - 2026) Analysis & Trends
Structure Therapeutics' Non-Current Assets history runs 5 years deep, the most recent figure standing at $17.5 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 3.54% year-over-year to $17.5 million; the TTM figure through Mar 2026 stood at $66.4 million (up 38.32% YoY), while the FY2025 annual figure was $13.6 million, up 12.34% from the prior year.
- Non-Current Assets for Q1 2026 stood at $17.5 million, up from $13.6 million in the prior quarter.
- The five-year high for Non-Current Assets was $18.1 million in Q3 2025, with the low at $1.2 million in Q1 2023.
- The 5-year median for Non-Current Assets is $9.5 million (2024), against an average of $10.3 million.
- The sharpest annual moves came in 2024 and 2026: Non-Current Assets surged 680.1% in 2024, then rose 3.54% in 2026.
- Structure Therapeutics' Non-Current Assets stood at $4.8 million in 2022, then jumped by 76.81% to $8.4 million in 2023, then jumped by 44.12% to $12.1 million in 2024, then climbed by 12.34% to $13.6 million in 2025, then rose by 28.73% to $17.5 million in 2026.
- Business Quant data shows GPCR's Non-Current Assets at $17.5 million in Q1 2026, $13.6 million in Q4 2025, and $18.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Structure Therapeutics | 11.65 Bn | 11.65 Bn | - | 53.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 53.39 Mn |
| Mar 31, 2026 | 17.53 Mn |
| Dec 31, 2025 | 13.62 Mn |
| Sep 30, 2025 | 18.14 Mn |
| Jun 30, 2025 | 17.15 Mn |
| Mar 31, 2025 | 16.93 Mn |
| Dec 31, 2024 | 12.12 Mn |
| Sep 30, 2024 | 9.57 Mn |
| Jun 30, 2024 | 9.41 Mn |
| Mar 31, 2024 | 7.87 Mn |
| Dec 31, 2023 | 8.41 Mn |
| Sep 30, 2023 | 6.41 Mn |
| Jun 30, 2023 | 1.21 Mn |
| Mar 31, 2023 | 1.20 Mn |
| Dec 31, 2022 | 4.76 Mn |